Literature DB >> 35074223

Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer.

Bharathi Muthusamy1, Nathan Pennell2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35074223     DOI： 10.1016/j.jtho.2021.11.012

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  [Exosomal FZD10 derived from non-small cell lung cancer cells promotes angiogenesis of human umbilical venous endothelial cells in vitro].

Authors:  X Wu; R Zhan; D Cheng; L Chen; T Wang; X Tang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-09-20

Review 2.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

3.  Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.

Authors:  Lingzhi Hong; Whitney E Lewis; Monique Nilsson; Sonia Patel; Susan Varghese; Melvin J Rivera; Robyn R Du; Pingjun Chen; Haley N Kemp; Waree Rinsurongkawong; Simon Heeke; Amy R Spelman; Yasir Y Elamin; Marcelo V Negrao; Boris Sepesi; Don L Gibbons; J Jack Lee; Jia Wu; Natalie I Vokes; John V Heymach; Jianjun Zhang; Xiuning Le
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

4.  Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.

Authors:  Jingjing Qu; Qian Shen; Yuping Li; Farhin Shaheed Kalyani; Li Liu; Jianya Zhou; Jianying Zhou
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.